Previous Statements by NKTR
» Nektar CEO Discusses Q3 2010 Results - Earnings Call Transcript
» Nektar Therapeutics Q2 2010 Earnings Call Transcript
» Nektar Therapeutics Q1 2010 Earnings Call Transcript
Nektar Therapeutics (NKTR) said on Wednesday that it would sell 13 million shares of common stock at $13.50 each.
A series of clinical trials will test the combination of Bristol-Myers Squibb's Opdivo with Nektar's NKTR-214 in multiple tumor types.